Insulet (PODD): Field Checks Indicate Longer Term Upside - Piper Jaffray

August 16, 2016 6:47 AM EDT
Get Alerts PODD Hot Sheet
Price: $43.05 -1.28%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade PODD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray analyst, Brooks West, reiterated his Overweight rating on shares of Insulet Corporation (NASDAQ: PODD) after the analyst attended the American Association of Diabetes Educators (AADE) annual meeting over the weekend where he spoke with members of the diabetes technology industry, certified diabetes educators (CDEs) and patients with type I diabetes.

The analyst's checks on PODD indicate continued strength for the core OmniPod business as patients, educators and even direct competitors have not only noticed a meaningful uptick in product quality (significantly improved out-of-box failure rates which, in contrast, were as high as ~30% under prior management) as well as discernible improvements in the company’s end-to-end operations.

Coming off a strong 2Q print he sees upside to longer term estimates from both a share gain/new patient add perspective both in the US and abroad, in addition to a steady decline in the OmniPod attrition rates (currently ~9%).

No change to the price target of $52.

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $44.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Brooks West

Add Your Comment